DeepFlow 3.0
The world's only commercial AI for flow cytometry
DeepFlow 3.0 is the fully upgraded version of our award-winning flow cytometry analysis platform. The world's only commercially available platform that combines traditional flow cytometry analysis with AI. Built as a full-stack, end-to-end solution, DeepFlow 3.0 enhances diagnostic efficiency while keeping pathologists in the loop — because the future of AI in pathology is not replacement, but collaboration.
AI-Driven Visualization
AI-Powered t-SNE Clustering
Automatically clusters cell populations using t-SNE dimensionality reduction, color-coded by immunophenotype. Instantly visualize complex multi-parameter data that would take hours to gate manually.
FlowSOM Network Analysis
Minimum spanning tree visualization reveals relationships between metaclusters. Integrated with traditional scatter plots for seamless comparison between AI-driven and conventional analysis.
Multi-Panel Heat Map Gating
Full panel gating displayed as heat maps for rapid pattern recognition. Supports Acute Leukemia, MRD, Lymphoma, MDS, PNH, and TBNK Lymphocyte Subset panels.
Interactive Scatter Plot Analysis
Multi-dimensional scatter plot grids with AI-identified populations highlighted. Integrated algorithms include GMM, T-SNE, CITRUS, FlowSOM, SPADE, and PhenoGraph.
Features
Automated Gating, Phenotyping & Reports
Performs end-to-end analysis from raw FCS data to final diagnostic report without manual gating.
HDPC Data Engine
High-dimensional population clustering engine detects aberrant populations at 0.01% sensitivity.
Simultaneous CD Marker Analysis
Evaluates all CD markers simultaneously across multi-color panels for comprehensive immunophenotyping.
50+ Clinical Flow Panels
Supports over 50 pre-configured clinical flow cytometry panels covering leukemia, lymphoma, MRD, and more.
Transfer Learning for Custom Panels
Adapts to new or custom panel configurations through transfer learning without retraining from scratch.
Broad File Format Compatibility
Compatible with FCS versions 2.0 through 3.1 and LMD data from all major flow cytometer manufacturers.
Trained on 300K+ Expert Cases
Built on a foundation of over 300,000 expert-diagnosed cases ensuring robust real-world performance.
Ultra-Low MRD Detection
Detects measurable residual disease at ultra-low cell percentages for sensitive post-therapy monitoring.
90% Faster Turnaround
Reduces report turnaround time by up to 90% compared to traditional manual analysis workflows.
